Fractyl Health announced that it initiated its Revita Global Registry Program in Germany to study its diabetes reversal treatment. On April 20, the Ethics Committee of the University of Freiburg (Germany) granted clearance for the initiation of a registry study. The study covers the Revita system in German hospitals. Patients in the registry have inadequately […]
Surgical
Endogenex taps former Medtronic executive as CEO
Endogenex, developer of a procedure for treating type 2 diabetes, announced today that it appointed Stacey Pugh as its new CEO. Pugh’s responsibilities at Minneapolis-based Endogenex include expanding the company’s clinical initiatives evaluating its ReCET procedure. ReCET — a novel, endoscopic, outpatient procedure — targets the underlying cellular abnormalities in the duodenum. These abnormalities contribute […]
Fractyl Health launches diabetes reversal treatment in Germany
Fractyl Health announced today that it commercially launched its Revita DMR system for diabetes reversal in Germany. Revita, an endoscopic procedural therapy, remodels the duodenal lining through hydrothermal ablation. This tackles a root cause of type 2 diabetes. Revita holds CE mark approval in Europe and established reimbursement in Germany recently. Lexington, Massachusetts-based Fractyl performed […]
Fractyl Health forms task force to understand root causes of type 2 diabetes
Fractyl Health announced today that it created the Erase T2D task force to research type 2 diabetes in the hopes of “erasing” the condition. The academic-industry scientific partnership aims to advance research on the role of the gut in metabolic disease. This, in turn, could catalyze future discoveries on understanding and erasing type 2 diabetes. […]
Data supports GI Dynamics’ type 2 diabetes treatment
GI Dynamics announced today that results from a registry for its EndoBarrier for type 2 diabetes were positive. Data from use of the EndoBarrier within the National Health Service (NHS) in the UK were presented by Dr. Robert Ryder of City Hospital (Birmingham, UK) at the American Diabetes Association Scientific Sessions last month, according to […]
Fractyl Health touts preliminary data from diabetes reversal study
Fractyl Health this week announced encouraging interim feasibility data from its diabetes reversal technology study. Lexington, Massachusetts–based Fractyl’s Revita-T2Di long-term open-label cohort assessed eight patients followed through at least four weeks having been treated. The company’s Revita system resurfaces the upper intestine lining (duodenal mucosa) to treat metabolic disease in patients with insulin-treated type 2 […]
Innocoll Biotherapeutics initiates Phase 3 trials for collagen drug-device
Innocoll Biotherapeutics announced today that it initiated two Phase 3 trials to support a label expansion for its collagen drug-device implant. Athlone, Ireland-based Innocoll’s trials are seeking label expansion for the FDA-approved Xaracoll (bupivacaine hydrochloride) implant, according to a news release. INN-CB-024, a Phase 3, randomized, double-blind, placebo-controlled study is evaluating the efficacy and safety […]
How Bionaut Labs aims to tackle brain tumors with microrobots
The roboticist Michael Shpigelmacher was one of the founders of PrimeSense, a robotic 3-D vision technology company Apple acquired in 2013. PrimeSense created technology empowering the Microsoft Xbox Kinect and the iPhone’s Face ID feature, allowing users to use facial recognition to unlock their phones. Now Shpigelmacher has set his sights on drug-delivery with Bionaut […]
AmacaThera raises $10.3M in oversubscribed Series A
AmacaThera announced today that it completed an oversubscribed $10.3 million Series A financing round. Lumira Ventures led the Series A funding, with existing investors Viva BioInnovator and Sprout BioVentures contributing as well. New investors BDC Capital Women in Technology Venture Fund, Inveready, MBX Capital, CR Capital Management, StandUp Ventures and MaRS IAF participated, too, according […]
OncoSec announces positive results in metastatic melanoma case study
The International Journal of Surgery Case Reports has published a case study on the use of the humanized antibody Keytruda (pembrolizumab) and tavokinogene telseplasmid (TAVO) from OncoSec (NSDQ:ONCS) for treating metastatic melanoma. The study involved a patient with stage IIB, pT3b melanoma who initially underwent tumor resection but experienced regional recurrence and later disease progression […]
